Grifols, S.A. (GRF.MC) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. GRF.MC files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 156.99% | 30.00% | Fail |
| Interest-bearing investments | 12.15% | 30.00% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 54.02% | 33.00% | Fail |
| Interest-bearing investments | 4.18% | 33.00% | Pass |
| Non-liquid assets | 92.52% | at least 20.00% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 54.02% | 33.33% | Fail |
| Cash + interest-bearing securities | 4.18% | 33.33% | Pass |
| Accounts receivable | 7.48% | 33.33% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 54.02% | 33.33% | Fail |
| Cash + interest-bearing securities | 4.18% | 33.33% | Pass |
| Accounts receivable | 7.48% | 50.00% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 156.69% | 33.00% | Fail |
| Cash + interest-bearing securities | 12.13% | 33.00% | Pass |
| Accounts receivable | 9.58% | 33.00% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 156.54% | 33.00% | Fail |
| Cash + interest-bearing securities | 12.11% | 49.00% | Pass |
| Accounts receivable | 9.57% | 49.00% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 156.54% | 33.33% | Fail |
| Cash + interest-bearing securities | 12.11% | 33.33% | Pass |
| Accounts receivable | 21.68% | 49.00% | Pass |
| Non-permissible income | 0.45% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 52.40 | NEUTRAL |
| Stochastic %K (14) | 48.80 | NEUTRAL |
| CCI (20) | -5.28 | NEUTRAL |
| Williams %R (14) | -51.20 | NEUTRAL |
| MACD (12,26,9) | -0.02 | SELL |
| ROC (10) | -0.89 | SELL |
| Momentum (10) | -0.09 | SELL |
| EMA (10) | 9.95 | SELL |
| SMA (10) | 9.95 | SELL |
| EMA (20) | 9.93 | SELL |
| SMA (20) | 9.95 | SELL |
| EMA (30) | 9.88 | SELL |
| SMA (30) | 10.02 | SELL |
| EMA (50) | 9.75 | BUY |
| SMA (50) | 9.71 | BUY |
| EMA (100) | 9.66 | BUY |
| SMA (100) | 9.36 | BUY |
| EMA (200) | 10.05 | SELL |
| SMA (200) | 9.82 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - General
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2024-12-31, figures in EUR.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
